Genetic and Clinical Features of Medullary Thyroid Carcinoma: The Experience of a Single Center in Costa Rica

被引:4
作者
Calvo, Javier [1 ]
Torrealba, Gabriel [2 ]
Saenz, Adriana [1 ]
Santamaria, Carlos [3 ]
Morera, Estela [3 ]
Alvarado, Silvia [1 ]
Roa, Yolanda [4 ]
Gonzalez, Michelle [1 ]
机构
[1] Hosp Rafael Angel Calderon Guardia, Dept Internal Med, Div Endocrinol, San Jose, Costa Rica
[2] Harvard Med Sch, Spaulding Rehabil Hosp, Neuromodulat Ctr, Boston, MA USA
[3] Natl Children Hosp, Mol Biol Lab, San Jose, Costa Rica
[4] Hosp Rafael Angel Calderon Guardia, Dept Pathol, San Jose, Costa Rica
关键词
D O I
10.1155/2016/9637173
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Activating mutations in the RET gene leads to medullary thyroid carcinoma (MTC). Guidelines encourage performing RET analysis in subjects with hereditary and sporadic disease. Materials and Methods. Design. Observational, case series report study. Patients. Subjects diagnosed with MTC, with a thyroidectomy performed in a single center in Costa Rica between the years 2006 and 2015. Diagnosis and Follow-Up. Pre- and postoperative calcitonin, RET mutation, and neck ultrasound and tomography were obtained. Results. 21 subjects with histological diagnosis of MTC were followed up. The average age at diagnosis was 52.0 +/- 15.7 years. The preoperative mean value of calcitonin was 1340 +/- 665 pg/mL. Evidence of RET mutation was found in 26.3% of the patients, with only 2 of them grouped in the same kindred. We found statistically significant differences in mean ages between mutated (38.4 +/- 20.2 y) versus nonmutated RET gene (54.6 +/- 11.8 y, p = 0.04). There were no significant differences regarding tumor size, metastases, and surgical reintervention. Conclusions. We report the results of RET mutation analysis in subjects with MTC in a single center of Costa Rica. The availability of this tool increases the probability of identifying familial MTC, with the benefit of detecting affected subjects and their relatives at an earlier age.
引用
收藏
页数:6
相关论文
共 25 条
[1]   Lessons to be learned from the clinical management of a MEN 2A patient bearing a novel 634/640/700 mutation of the RET proto-oncogene [J].
Conzo, Giovanni ;
Circelli, Luisa ;
Pasquali, Daniela ;
Sinisi, Antonio ;
Sabatino, Lina ;
Accardo, Giacomo ;
Renzullo, Andrea ;
Santini, Luigi ;
Salvatore, Francesco ;
Colantuoni, Vittorio .
CLINICAL ENDOCRINOLOGY, 2012, 77 (06) :934-936
[2]   Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer:: A 10-year follow-up study [J].
Elisei, Rossella ;
Cosci, Barbara ;
Romei, Cristina ;
Bottici, Valeria ;
Renzini, Giulia ;
Molinaro, Eleonora ;
Agate, Laura ;
Vivaldi, Agnese ;
Faviana, Pinuccia ;
Basolo, Fulvio ;
Miccoli, Paolo ;
Berti, Piero ;
Pacini, Furio ;
Pinchera, Aldo .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (03) :682-687
[3]   FINE NEEDLE ASPIRATION AND MEDULLARY THYROID CARCINOMA: THE RISK OF INADEQUATE PREOPERATIVE EVALUATION AND INITIAL SURGERY WHEN RELYING UPON FNAB CYTOLOGY ALONE [J].
Essig, Garth F., Jr. ;
Porter, Kyle ;
Schneider, David ;
Debora, Arpaia ;
Lindsey, Susan C. ;
Busonero, Giulia ;
Fineberg, Daniel ;
Fruci, Barbara ;
Boelaert, Kristien ;
Smit, Johannes W. ;
Meijer, Johannes Arnoldus Anthonius ;
Duntas, Leonidas ;
Sharma, Neil ;
Costante, Giuseppe ;
Filetti, Sebastiano ;
Sippel, Rebecca S. ;
Biondi, Bernadette ;
Topliss, Duncan J. ;
Pacini, Furio ;
Maciel, Rui M. B. ;
Walz, Patrick C. ;
Kloos, Richard T. .
ENDOCRINE PRACTICE, 2013, 19 (06) :920-927
[4]   Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form [J].
Figlioli, Gisella ;
Landi, Stefano ;
Romei, Cristina ;
Elisei, Rossella ;
Gemignani, Federica .
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2013, 752 (01) :36-44
[5]   Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations [J].
Fitze, G ;
Schierz, M ;
Bredow, J ;
Saeger, HD ;
Roesner, D ;
Schackert, HK .
ANNALS OF SURGERY, 2002, 236 (05) :570-575
[6]   Management of advanced medullary thyroid cancer [J].
Hadoux, Julien ;
Pacini, Furio ;
Tuttle, R. Michael ;
Schlumberger, Martin .
LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (01) :64-71
[7]   Update on Medullary Thyroid Cancer [J].
Hu, Mimi I. ;
Ying, Anita K. ;
Jimenez, Camilo .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2014, 43 (02) :423-+
[8]   Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic [J].
Jindrichová, S ;
Vcelák, J ;
Vlcek, P ;
Neradilová, M ;
Nemec, J ;
Bendlová, B .
JOURNAL OF ENDOCRINOLOGY, 2004, 183 (02) :257-265
[9]  
Kebebew E, 2000, CANCER-AM CANCER SOC, V88, P1139, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO
[10]  
2-Z